Results 181 to 190 of about 48,064 (345)

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

open access: yesMedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi   +5 more
wiley   +1 more source

A Case of Epidermolytic Ichthyosis with Massive Hyperkeratosis Successfully Treated with Systemic Etretinate [PDF]

open access: gold, 2023
Eijiro Akasaka   +4 more
openalex   +1 more source

Hyperkeratosis Blenorrhagica [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1921
openaire   +2 more sources

The Genetics of Acne

open access: yesAnnals of Human Genetics, Volume 89, Issue 5, Page 333-341, September 2025.
ABSTRACT This review addresses the genetics of acne vulgaris, the most common skin disease. It is characterized by the presence of comedones (blackheads), papules, and pustules. The condition is associated with sebaceous glands in the face and chest, which produce an oily substance called sebum.
Maurice A. M. Van Steensel
wiley   +1 more source

Acrokeratosis Paraneoplastica-like Findings as a Manifestation of Systemic Lupus Erythematosus

open access: yesActa Dermato-Venereologica, 2018
Laura Huilaja   +3 more
doaj   +1 more source

Incidencia de la eritroleucoplasia en la cavidad bucal Incidence of erythroleukoplakia in the oral cavity

open access: yesMedisan, 2012
Se efectuó un estudio descriptivo y transversal de 20 mujeres y hombres mayores de 19 años, adictos al tabaco, atendidos en la consulta estomatológica del Policlínico de Especialidades del Hospital Provincial Docente "Saturnino Lora Torres" de Santiago ...
Gladys Aída Estrada Pereira   +2 more
doaj  

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2262-2272, August 2025.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy